![Teva Branded Pharmaceutical Products R&D;, . An electronic inhaler add-on module which store and transmit information related to inhaler use (eModule) PDR0000401 FCC ID 2AJVSPDR0000401 Teva Branded Pharmaceutical Products R&D;, . An electronic inhaler add-on module which store and transmit information related to inhaler use (eModule) PDR0000401 FCC ID 2AJVSPDR0000401](https://fccid.io/images/device/2AJVS/PDR0000401/External-Photos-1246BBA1.jpg)
Teva Branded Pharmaceutical Products R&D;, . An electronic inhaler add-on module which store and transmit information related to inhaler use (eModule) PDR0000401 FCC ID 2AJVSPDR0000401
![Characterizing patient compliance over six months in remote digital trials of Parkinson's and Huntington disease | BMC Medical Informatics and Decision Making | Full Text Characterizing patient compliance over six months in remote digital trials of Parkinson's and Huntington disease | BMC Medical Informatics and Decision Making | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12911-018-0714-7/MediaObjects/12911_2018_714_Fig1_HTML.png)
Characterizing patient compliance over six months in remote digital trials of Parkinson's and Huntington disease | BMC Medical Informatics and Decision Making | Full Text
![PDF) Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors PDF) Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors](https://i1.rgstatic.net/publication/262784686_Phase_1_dose-escalation_study_of_the_PARP_inhibitor_CEP-9722_as_monotherapy_or_in_combination_with_temozolomide_in_patients_with_solid_tumors/links/549d0f070cf2b8037138c9c9/largepreview.png)
PDF) Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors
![Teva Branded Pharmaceutical Products R&D;, . An electronic inhaler add-on module which store and transmit information related to inhaler use (eModule) PDR0000401 FCC ID 2AJVSPDR0000401 Teva Branded Pharmaceutical Products R&D;, . An electronic inhaler add-on module which store and transmit information related to inhaler use (eModule) PDR0000401 FCC ID 2AJVSPDR0000401](https://cdn-0.fccid.io/images/device/2AJVS/PDR0000401/Users-Manual-543D7757.jpg)
Teva Branded Pharmaceutical Products R&D;, . An electronic inhaler add-on module which store and transmit information related to inhaler use (eModule) PDR0000401 FCC ID 2AJVSPDR0000401
![Teva Branded Pharmaceutical Products R&D;, . An electronic inhaler add-on module which store and transmit information related to inhaler use (eModule) PDR0000401 FCC ID 2AJVSPDR0000401 Teva Branded Pharmaceutical Products R&D;, . An electronic inhaler add-on module which store and transmit information related to inhaler use (eModule) PDR0000401 FCC ID 2AJVSPDR0000401](https://cdn-0.fccid.io/images/device/2AJVS/PDR0000401/Internal-Photos-645EADB6.jpg)
Teva Branded Pharmaceutical Products R&D;, . An electronic inhaler add-on module which store and transmit information related to inhaler use (eModule) PDR0000401 FCC ID 2AJVSPDR0000401
![Assessment of Alcohol-Induced Dose Dumping with a Hydrocodone Bitartrate Extended-Release Tablet Formulated with CIMA® Abuse Deterrence Technology – topic of research paper in Clinical medicine. Download scholarly article PDF and read for Assessment of Alcohol-Induced Dose Dumping with a Hydrocodone Bitartrate Extended-Release Tablet Formulated with CIMA® Abuse Deterrence Technology – topic of research paper in Clinical medicine. Download scholarly article PDF and read for](https://cyberleninka.org/viewer_images/1378020/f/1.png)
Assessment of Alcohol-Induced Dose Dumping with a Hydrocodone Bitartrate Extended-Release Tablet Formulated with CIMA® Abuse Deterrence Technology – topic of research paper in Clinical medicine. Download scholarly article PDF and read for
![Real-world Adherence and Persistence with Bisphosphonate Therapy in Postmenopausal Women: A Systematic Review - Clinical Therapeutics Real-world Adherence and Persistence with Bisphosphonate Therapy in Postmenopausal Women: A Systematic Review - Clinical Therapeutics](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f6221b10-c6d7-43a8-bfe3-6d790ad1bfec/gr1_lrg.jpg)